Polymorphic forms of deferasirox ( icl670a)
A technology of crystal form and type, applied in the field of crystal form A, therapeutic treatment, which can solve problems such as differences
Active Publication Date: 2009-09-23
NOVARTIS AG
View PDF1 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
However, it is also known that different crystalline forms of the same drug may have very different properties in certain pharmaceutically important
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0184] Example 1 : Form A of 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid prepared using THF / ethanol and HXF
Embodiment 2
[0185] Example 2 : Form A of 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid prepared using toluene and THF
Embodiment 3
[0186] Example 3 : Form A of 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid prepared using methanol / THF
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
The invention relates to crystalline forms of 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1- yl]benzoic acid and to its amorphous form, to processes for the preparation thereof, to compositions containing the same and their uses for the manufacture of a medicament for the treatment of the human body.
Description
[0001] The present invention relates to new crystalline forms of 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid, processes for preparing these crystalline forms, combinations containing these crystalline forms and the use of these crystalline forms in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. Background of the invention [0002] The drug 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid is an orally active iron chelator indicated for the treatment of transfusion dependence iron overload in transfusion dependent anemias, particularly thalassemia major, thalassemia intermedia and sickle cell disease, to reduce iron-related morbidity and mortality. 4-[3,5-Bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid is also useful in the treatment of hemochromatosis. In general, the preparation of 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid is known in the art. However, it is also known that differe...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More IPC IPC(8): C07D249/08A61K31/4196A61P7/00
CPCC07D249/08A61P7/00
Inventor M·马兹
Owner NOVARTIS AG
